• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.235 -0.025 (-1.98%)
Streaming Delayed Price Updated: 9:44 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
August 27, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
August 13, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
August 06, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
August 01, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
June 01, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 23, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
May 22, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
May 13, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
May 06, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
April 07, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
March 13, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
March 03, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in March Investor Conference
February 26, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
February 25, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
February 18, 2025
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
February 13, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in February Investor Conferences
February 04, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
January 29, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
January 28, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
December 12, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in December Investor Conferences
November 19, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
November 18, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
November 07, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
November 07, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
November 05, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in November Investor Conferences
November 04, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
October 30, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
October 29, 2024
From Allogene Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap